Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients : The ETHRA Study
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved..
BACKGROUND/AIM: To investigate the efficacy (prognosis, coagulation/inflammation biomarkers) and safety (bleeding events) of different anticoagulation dosages in COVID-19 inpatients.
PATIENTS AND METHODS: COVID-19 inpatients (Athens, Greece) were included. The "Enhanced dose THRomboprophylaxis in Admissions (ETHRA)" protocol was applied in certain Departments, suggesting the use of intermediate anticoagulation dosage. The primary endpoint was a composite of intubation/venous thromboembolism/death. Inflammation/coagulation parameters were assessed.
RESULTS: Among 127 admissions, 95 fulfilled the inclusion criteria. Twenty-one events (4 deaths, 17 intubations) were observed. Regression analysis demonstrated significant reduction of events with intermediate or therapeutic dosage [HR=0.16 (95%CI=0.05-0.52) p=0.002; HR=0.17 (0.04-0.71) p=0.015, respectively]. D-Dimer values were higher in those who met the composite endpoint. Intermediate dosage treatment was associated with decreased values of ferritin. Three patients (3%) had minor hemorrhagic complications.
CONCLUSION: Anticoagulation treatment (particularly intermediate dosage) appears to have positive impact on COVID-19 inpatients' prognosis by inhibiting both coagulation and inflammatory cascades.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
In vivo (Athens, Greece) - 35(2021), 1 vom: 12. Jan., Seite 653-661 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Poulakou, Garyphallia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 25.01.2021 Date Revised 27.08.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.21873/invivo.12305 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319663469 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319663469 | ||
| 003 | DE-627 | ||
| 005 | 20231225171929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21873/invivo.12305 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319663469 | ||
| 035 | |a (NLM)33402523 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poulakou, Garyphallia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients |b The ETHRA Study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2021 | ||
| 500 | |a Date Revised 27.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | ||
| 520 | |a BACKGROUND/AIM: To investigate the efficacy (prognosis, coagulation/inflammation biomarkers) and safety (bleeding events) of different anticoagulation dosages in COVID-19 inpatients | ||
| 520 | |a PATIENTS AND METHODS: COVID-19 inpatients (Athens, Greece) were included. The "Enhanced dose THRomboprophylaxis in Admissions (ETHRA)" protocol was applied in certain Departments, suggesting the use of intermediate anticoagulation dosage. The primary endpoint was a composite of intubation/venous thromboembolism/death. Inflammation/coagulation parameters were assessed | ||
| 520 | |a RESULTS: Among 127 admissions, 95 fulfilled the inclusion criteria. Twenty-one events (4 deaths, 17 intubations) were observed. Regression analysis demonstrated significant reduction of events with intermediate or therapeutic dosage [HR=0.16 (95%CI=0.05-0.52) p=0.002; HR=0.17 (0.04-0.71) p=0.015, respectively]. D-Dimer values were higher in those who met the composite endpoint. Intermediate dosage treatment was associated with decreased values of ferritin. Three patients (3%) had minor hemorrhagic complications | ||
| 520 | |a CONCLUSION: Anticoagulation treatment (particularly intermediate dosage) appears to have positive impact on COVID-19 inpatients' prognosis by inhibiting both coagulation and inflammatory cascades | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a anticoagulation | |
| 650 | 4 | |a intermediate dosage | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a thromboprophylaxis | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Dimakakos, Evangelos |e verfasserin |4 aut | |
| 700 | 1 | |a Kollias, Anastasios |e verfasserin |4 aut | |
| 700 | 1 | |a Kyriakoulis, Konstantinos G |e verfasserin |4 aut | |
| 700 | 1 | |a Rapti, Vasiliki |e verfasserin |4 aut | |
| 700 | 1 | |a Trontzas, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Thanos, Charalampos |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelrasoul, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Vantana, Theodora |e verfasserin |4 aut | |
| 700 | 1 | |a Leontis, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Kakalou, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Argyraki, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Baraboutis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Michelakis, Evangelos |e verfasserin |4 aut | |
| 700 | 1 | |a Giamarellos-Bourboulis, Evangelos |e verfasserin |4 aut | |
| 700 | 1 | |a Dimakou, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Tsoukalas, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Rapti, Angeliki |e verfasserin |4 aut | |
| 700 | 1 | |a Michelakis, Evangelos D |e verfasserin |4 aut | |
| 700 | 1 | |a Syrigos, Konstantinos N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t In vivo (Athens, Greece) |d 1992 |g 35(2021), 1 vom: 12. Jan., Seite 653-661 |w (DE-627)NLM012776912 |x 1791-7549 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:1 |g day:12 |g month:01 |g pages:653-661 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21873/invivo.12305 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2021 |e 1 |b 12 |c 01 |h 653-661 | ||